Interpretation of immunofluorescence slides by deep learning techniques: anti-nuclear antibodies case study

Nowadays, diseases are increasing in numbers and severity by the hour. Immunity diseases, affecting 8\% of the world population in 2017 according to the World Health Organization (WHO), is a field in medicine worth attention due to the high rate of disease occurrence classified under this category. This work presents an up-to-date review of state-of-the-art immune diseases healthcare solutions. We focus on tackling the issue with modern solutions such as Deep Learning to detect anomalies in the early stages hence providing health practitioners with efficient tools. We rely on advanced deep learning techniques such as Convolutional Neural Networks (CNN) to fulfill our objective of providing an efficient tool while providing a proficient analysis of this solution. The proposed solution was tested and evaluated by the immunology department in the Principal Military Hospital of Instruction of Tunis, which considered it a very helpful tool

Outcomes of treatment of severe COVID-19 pneumonia with tocilizumab: a report of two cases from Tunisia

The SARS CoV-2 pandemic is a global health threat with high morbidity and mortality (1 to 4%) rates. COVID-19 is correlated with important immune disorders, including a “cytokine storm”. A new therapeutic approach using the immunomodulatory drug, Anti-IL6 (tocilizimub), has been proposed to regulate it. We report here the first Tunisian experience using tocilizimub in two severe cases of COVID-19 pneumonia. The diagnosis was confirmed by chest scan tomography. Biological parameters showed a high level of Interleukin-6 (IL-6) that increased significantly during hospitalization. The patients developed hypoxia, so they received intravenously 8 mg/kg body weight tocilizumab. There was a resultant decrease in the level of IL6, with clinically good evolution. Blocking the cytokine IL-6 axis is a promising therapy for patients developing COVID-19 pathology